Kerstens M N, Buter H, Navis G J, Dullaart R P F
University Hospital Groningen, The Netherlands.
Eur J Clin Invest. 2002 Jul;32(7):513-8. doi: 10.1046/j.1365-2362.2002.01013.x.
It has been suggested that an altered setpoint of the 11betaHSD-mediated cortisol to cortisone interconversion towards cortisol contributes to sodium retention in nephrotic syndrome patients. We studied the parameters of 11betaHSD activity in proteinuric patients, in particular its activity at the kidney level. We also studied the effect of angiotensin-II receptor blockade on the parameters of 11betaHSD activity.
Serum cortisol/cortisone ratio and the urinary ratios of (tetrahydrocortisol + allo-tetrahydrocortisol)/tetrahydrocortisone [(THF + allo-THF)/THE] and of urinary free cortisol/free cortisone (UFF/UFE) were measured in eight proteinuric patients and compared with eight matched, healthy subjects. Patients were subsequently studied after 4 weeks' treatment with losartan 50 mg day-1 and placebo, respectively.
No significant differences between the proteinuric patients and the healthy subjects were observed in the serum cortisol, serum cortisone, serum cortisol to cortisone ratio, or in the urinary excretions of THF, allo-THF, THE, sum of cortisol metabolites, or the (THF + allo-THF)/THE ratio. Urinary free cortisol excretion and the UFF/UFE ratio were lower in the proteinuric patients than in the healthy subjects (56 +/- 21 vs. 85 +/- 24 pmol min-1, P < 0.05, and 0.39 +/- 0.07 vs. 0.63 +/- 0.28, P < 0.05, respectively). Mean arterial pressure and proteinuria were reduced significantly during losartan treatment, but without concomitant changes in peripheral cortisol metabolism.
Increased renal inactivation of cortisol in proteinuric patients does not support the contention that altered 11betaHSD activity contributes to sodium retention in patients with nephrotic syndrome. Losartan 50 mg d.d. reduces mean arterial pressure and proteinuria, but does not exert a significant effect on the cortisol to cortisone interconversion.
有研究表明,11β羟类固醇脱氢酶(11βHSD)介导的皮质醇向可的松的相互转化的设定点改变,导致皮质醇水平升高,这可能是肾病综合征患者钠潴留的原因之一。我们研究了蛋白尿患者中11βHSD活性的参数,特别是其在肾脏水平的活性。我们还研究了血管紧张素II受体阻滞剂对11βHSD活性参数的影响。
测量了8例蛋白尿患者的血清皮质醇/可的松比值、尿中(四氢皮质醇+表四氢皮质醇)/四氢可的松[(THF+allo-THF)/THE]比值以及尿游离皮质醇/游离可的松(UFF/UFE)比值,并与8例匹配的健康受试者进行比较。随后,患者分别接受50mg/天氯沙坦和安慰剂治疗4周后进行研究。
蛋白尿患者与健康受试者在血清皮质醇、血清可的松、血清皮质醇与可的松比值、THF、allo-THF、THE、皮质醇代谢产物总和或(THF+allo-THF)/THE比值的尿排泄方面均未观察到显著差异。蛋白尿患者的尿游离皮质醇排泄量和UFF/UFE比值低于健康受试者(分别为56±21与85±24pmol/min,P<0.05;0.39±0.07与0.63±0.28,P<0.05)。氯沙坦治疗期间平均动脉压和蛋白尿显著降低,但外周皮质醇代谢无相应变化。
蛋白尿患者中皮质醇肾脏失活增加并不支持11βHSD活性改变导致肾病综合征患者钠潴留的观点。50mg/d的氯沙坦可降低平均动脉压和蛋白尿,但对皮质醇向可的松的相互转化无显著影响。